Which GLP-1 Drug Stocks to Watch in 2025

The GLP-1 weight loss drug market is expected to exceed $100 billion annually, giving stock market investors plenty to be excited about for the top drug stocks in this niche. This video reviews the key terminology and considerations of this market while comparing the fundamentals of three pharmaceutical stocks at the forefront of the GLP-1 revolution.

💎 Get more from your stock research with Seeking Alpha Premium!
Save $$ on your first year and support my channel with the link below.
➡️ https://40finance.com/seekingalpha

GLP-1 drugs:
Novo Nordisk liraglutide (Saxenda)
Novo Nordisk semaglutide (Ozempic for diabetes and Wegovy for obesity)
Eli Lilly tirzepatide (Mounjaro for diabetes and Zepbound for obesity)

The following stocks are featured in this video:
OZEM Roundhill Glp-1 & Weight Loss ETF
LLY Eli Lilly and Company
NVO Novo Nordisk A/S
VKTX Viking Therapeutics, Inc.

Which GLP-1 pharmaceutical stocks are you watching in 2025? Post your favorite picks in the comments!


DISCLAIMER: This post includes my opinions (which may not reflect those of Seeking Alpha) and is not individualized investment advice. Some of the product or service links featured here are affiliate links. I may receive a commission for purchases made through these links.